Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

NCT02465567 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

8588

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: BGF MDI 320/14.4/9.6 μg
DRUG: GFF MDI 14.4/9.6 μg
DRUG: BGF MDI 160/14.4/9.6 μg
DRUG: BFF MDI 320/9.6 μg

Sponsor

Pearl Therapeutics, Inc.